USPTO Patent Grant for Bispecific Antibodies
Summary
The USPTO has granted a patent (US12577314B2) to ABL BIO INC. for bispecific antibodies designed to treat diseases related to BCMA and/or 4-1BB proteins. The patent covers the antibody's structure and its therapeutic applications.
What changed
The United States Patent and Trademark Office (USPTO) has issued patent US12577314B2 to ABL BIO INC. This patent covers novel anti-BCMA/anti-4-1BB bispecific antibodies or antigen-binding fragments thereof. The invention is described as having high binding affinity to both BCMA and 4-1BB proteins and being useful for preventing or treating diseases associated with these proteins.
This patent grant is primarily an intellectual property matter and does not impose direct compliance obligations on regulated entities. However, it signifies a new development in the therapeutic landscape for BCMA/4-1BB related diseases, potentially impacting market exclusivity and future research and development strategies for other companies in the oncology and immunology space. Companies operating in this therapeutic area should be aware of this granted patent and its scope.
Archived snapshot
Mar 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Anti-BCMA/anti-4-1BB bispecific antibodies and uses thereof
Grant US12577314B2 Kind: B2 Mar 17, 2026
Assignee
ABL BIO INC.
Inventors
Kyung Jin Park, Yang Soon Lee, Sae Yi Lim, Hye Jin Chung, Kyeong Su Park, Yong Gyu Son, Seong Gyu Seon, Won Jun Son, Eun Jung Kim, Jae Hyun Eom, Ui Jung Jung, Min Ji Park, Jung Hyeon Hong
Abstract
An anti-B-cell maturation antigen (BCMA)/anti-4-1BB bispecific antibody or an antigen-binding fragment thereof, and use thereof, are provided. The bispecific antibody or an antigen-binding fragment thereof may have high binding affinity to both of a BCMA protein and a 4-1BB protein and may be effectively used to prevent or treat a disease related to BCMA, 4-1BB, or both thereof.
CPC Classifications
C07K 16/468 C07K 16/2878 A61P 35/00
Filing Date
2020-12-10
Application No.
17783344
Claims
11
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.